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Abstract
Lynch syndrome (LS) is a disorder caused by mismatch repair gene mutations, which have been recognized to be
associated with an increased frequency of colorectal and extracolorectal tumors. However, it remains controversial
as to whether total or segmental colectomy should be performed to treat colorectal cancer in patients with LS. A
58-year-old male underwent total colectomy with ileostomy for advanced transverse colon cancer. He was also
found to have LS based on his characteristic family history and the findings of a preoperative examination, including a
microsatellite instability analysis of past multiple metachronous cancers. The postoperative histological findings
showed mucinous adenocarcinoma without lymph node metastasis, and the loss of the MSH2 protein
expression was confirmed on an immunohistochemical examination. The present case provided important
information on the clinical management of multiple developing metachronous colorectal cancers in patients
with LS.
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Background
Lynch syndrome (LS) is a dominantly inherited syn-
drome characterized by the development of a variety of
cancers in the colorectum, endometrium, skin, ovaries,
urothelial tissue, small intestine, pancreas, and hepato-
biliary tract [1, 2]. Lynch syndrome-associated tumors
are caused by germline mutations in DNA mismatch re-
pair (MMR) genes, including MLH1, MSH2, MSH6, and
PMS2 (MLH1 and MSH2 account for the majority of
cases) [3]. Moreover, deletions of the terminal codon of
the EPCAM gene, located upstream from the MSH2
gene, result in silencing of the MSH2 gene and produce
a phenotype very similar to LS [4]. The loss of function
of this pathway leads to microsatellite instability (MSI)
with an increased risk of colorectal and extracolorectal
cancer, comprising 2–7 % of all colorectal cancers
(CRCs) [2, 5, 6].
The conventional identification of LS patients relies on
the application of various clinical guidelines, including
the Amsterdam II criteria and revised Bethesda guide-
lines for LS. Subsequently, a second screening, which in-
cludes an MSI analysis and/or an immunohistochemical
analysis is performed for the patients who match the
prior clinical guidelines. A definitive diagnosis is made
according to analyses of mismatch repair genes. The
clinical characteristics of this disease include a tendency
to occur in the proximal colon, an increased risk of
early-onset cancer, rapid progression, and a relatively
good prognosis [2, 5, 7, 8]. Mutation carriers have a risk
of developing CRC of approximately 50–82 % through-
out their lifetime, with occasional relapses after treat-
ment [5, 9, 10].
However, it remains controversial as to whether total
or segmental colectomy should be used to treat CRC in
patients with LS. Since CRC does not always develop in
LS patients with a penetrance of approximately 80 %
and conventional surveillance with colonoscopy may be
performed as nonsurgical therapy for tumors prior to
the development of advanced cancer, prophylactic total
colectomy is not frequently performed in cases of Lynch
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syndrome, unlike that observed in familial adenomatous
polyposis (FAP) [1]. Nevertheless, prophylactic total col-
ectomy may be indicated if the frequency of CRC is
high, and it is difficult to prevent progression to ad-
vanced cancer due to rapid development.
The present report describes the case of a patient with
LS in whom a third colon cancer was detected in an ad-
vanced stage within 1 year after periodic colonoscopy.
Total colectomy with ileostomy was administered con-
sidering the patient’s history of multiple metachronous
colon and extracolorectal cancers diagnosed preopera-
tively according to an MSI analysis using previous can-
cer tissues.
Case presentation
A 58-year-old Japanese male was referred to our hospital
for the treatment of advanced transverse colon cancer
diagnosed based on annual colonoscopy findings.
The patient’s past medical history included ulcerative
colitis (UC), which had been treated with proctectomy
and a colonic stoma in his 20s; although this condition
was not currently being followed up, adenocarcinoma of
the stomach was treated via distal gastrectomy at
53 years of age and primary colon cancer (of the trans-
verse and ascending colon) treated via endoscopic mu-
cosal resection (EMR) and segmental colectomy at 55
and 56 years of age, respectively. Additionally, colonos-
copy had revealed multiple adenomatous polyps within
the last 6 years.
No apparent abnormalities were observed on a phys-
ical examination except for a surgical scar on the pa-
tient’s midline and the colostomy site in the left lower
quadrant of the abdomen.
The hematological laboratory data on admission were
as follows: white blood cell count = 6,390/μl (normal
range 4500–9000); hemoglobin = 9.6 g/dl (normal range
13.6–17.0); platelet count = 31.3 × 104/μl (normal range
14.0–36.0); albumin = 4.5 g/dl (normal range 4.0–5.0);
carcinoembryonic antigen = 1.8 ng/ml (normal range
0–5.0); carbohydrate antigen 19–9 = 16 U/ml (normal
range 0–37.0).
Colonoscopy disclosed a malignant appearing deep
ulcerated lesion occupying half of the lumen in the
transverse colon (Fig. 1a). An adenomatous polyp in the
cecum was subsequently removed, without any signs of
recurrence of UC. A biopsy of the transverse colon
tumor showed poorly differentiated adenocarcinoma
with the accumulation of mucus.
Thoracoabdominal computed tomography (CT) and
positron emission tomography (PET)-CT demonstrated
no systemic metastasis of colon cancer.
The pedigree of the patient’s family is shown in Fig. 2.
His father had suffered from colon cancer at 43 years of
age and gastric cancer at 73 years of age, his paternal
aunt had a history of bladder/urinary tract cancer, and
his paternal grandfather had died due to an unknown
cancer; genetic testing was not performed in these indi-
viduals. The patient was suspected of having LS based
on the Amsterdam II criteria and revised Bethesda
guidelines as well as his history of metachronous cancer.
Therefore, we conducted an MSI analysis of the previous
gastric and colon cancer tissues to confirm the possible
role of LS, the results of which revealed MSI-high status
in both cancer tissues (Fig. 3). These findings strongly
suggested a diagnosis of LS. Furthermore, the frequency
of CRC was high, and advanced CRC was detected
within one year after periodic colonoscopy. We therefore
recommended that the patient undergo total colectomy.
We successfully performed total colectomy with ileos-
tomy after discussing the options for surgery with the
patient and his family (Fig. 1b). The histopathological
findings of the surgical specimen showed a type 2 tumor
(50 × 40 mm) in the transverse colon exhibiting heterogen-
eity of poorly differentiated adenocarcinoma, mucinous
adenocarcinoma, and well-differentiated adenocarcinoma.
However, no lymph node metastasis was detected
(T4a N0 M0 Stage IIB [according to the 7th edition
of the International Union Against Cancer TNM clas-
sification, Fig. 4a, b]).
Immunostaining for mismatch repair proteins revealed
clearly positive MSH2 staining in the non-cancerous
lesions, with no staining in the cancerous lesions. These
findings suggested that the patient had LS related to
MSH2 deficiency (Fig. 4c, d).
The patient’s postoperative course was uneventful, and
he was discharged from our hospital 29 days after
undergoing surgery. Capecitabine was administered as
adjuvant chemotherapy for 6 months, with no signs of
recurrence for over 1 year. After genetic counseling,
germline testing for MMR (MLH1 and MSH2) gene re-
vealed no mutation in MLH1 and p.G40S (GGC > AGC)
mutation in MSH2 in heterozygote. Currently, EPCAM
gene mutation analysis is not available in Japan.
Discussion
We herein report a case of LS in a patient who under-
went total colectomy based on his history of multiple
metachronous colon and extracolorectal cancers diag-
nosed preoperatively according to an MSI analysis using
previous cancer tissues. To confirm the diagnosis for LS,
MSI status is not sufficient; germline mutation analysis
which usually takes several weeks should be performed
to confirm the diagnosis of LS, although it is not always
available before operation. Moreover, germline mutation
analysis does not always come to the conclusion if the
alteration turned out to be a variant of unknown signifi-
cance as we detected in MSH2 gene as missense muta-
tion p.G40S. Therefore, germline mutation analysis of
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the terminal codon of the EPCAM gene might be neces-
sary to find a pathological mutation [4]. In addition,
there is the report that 45 % of MSH2 mutations are de-
tected in multiplex ligation-dependent probe amplifica-
tion (MLPA) [11]. So, MLPA might be considered for
analysis of the MMR gene mutation that was suspected
by MSI and immunohistochemistry (IHC) if there is no
mutation detected by PCR-direct sequence.
CRC with LS develops from precursor adenoma-
tous polyps. Several studies have suggested that this
premalignant lesion related to LS tends to undergo
more rapid development in LS patients than in pa-
tients who do not have LS [7, 8]. According to the
pathological characteristics of LS, a high degree of
lymphocyte infiltration is often observed in the cancer
tissue, with the tumors being poorly differentiated and
Fig. 2 The patient’s pedigree. Three family members among two generations were affected by Lynch syndrome-associated tumors. The patient’s
family satisfied the Amsterdam II criteria and revised Bethesda guidelines for a diagnosis of Lynch syndrome
Fig. 1 a Colonoscopy disclosed a type 2 tumor in the transverse colon that was histologically diagnosed as poorly differentiated
adenocarcinoma. b Macroscopic view of the resected total colon with cancer. A type 2 tumor (50 mm) is noted
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Fig. 3 Results of the microsatellite instability (MSI) analysis. The gastric cancer and CRC tissues exhibited a high level of MSI based on the number
of replication errors. ※poor in amplification
Fig. 4 a Detailed microscopic view. The tumor displays heterogeneity of poorly differentiated adenocarcinoma (arrowhead) and well-differentiated
adenocarcinoma (arrow). b The lesion consists of mucinous adenocarcinoma. c Immunostaining for the mismatch repair protein MLH1 clearly showed
positive staining in the cancerous tissue (arrow) and non-cancerous tissue. d Immunostaining for the mismatch repair protein MSH2 showed positive
staining in the non-cancerous tissue (arrowhead), with no staining in the cancerous tissue (arrow)
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mucinous and/or comprising signet ring cell carcinoma
[2, 5, 12].
Conventional surveillance with colonoscopy is recom-
mended in LS patients, with a surveillance interval of 1
to 2 years beginning at the age of 20–25 [9, 13, 14]. The
aim of this surveillance is to detect and remove adenoma-
tous polyps before they progress to cancer [6, 10, 15, 16].
Previous studies have reported that periodic examinations
with colonoscopy reduce the risk of malignancy by 62 %,
with a significant reduction in mortality due to CRC
[15, 17–19].
However, several reports have found that colono-
scopic surveillance is associated with a small risk
(approximately 6 %) of developing CRC, with 10 % of
these cancers being in the advanced stage, as prema-
lignant lesions generally develop rapidly and are mor-
phologically flat, making them difficult to identify on
colonoscopy [9, 13]. One study reported a significant
rate of missed adenomas of up to 55 % using conven-
tional colonoscopy [20].
CRC with LS is usually treated with either segmental
colectomy or total colectomy with ileorectal anasto-
mosis. The selection of the surgical procedure for CRC
in LS patients is controversial due to the lack of available
information regarding treatment. For example, there are
no prospective studies assessing the survival benefits
and QOL of large populations. Some authors recom-
mend the use of total colectomy to treat CRC in LS
patients based on findings showing that the risk of meta-
chronous CRC following segmental colectomy ranges
between 11 and 45 % over follow-up periods of 8 to
15 years [6, 9, 21].
However, total colectomy with ileorectal anastomosis
is well known to be associated with a decrease in the
quality of life due to an increase in stool frequency and a
more liquid stool consistency [22]. Total colectomy is
also considered for application as partial prophylactic
therapy, as there is a possibility for the subsequent oc-
currence of extracolonic cancer. Additionally, since CRC
does not always develop in LS patients and conventional
surveillance with colonoscopy may be performed as non-
surgical therapy for tumors prior to the development of
advanced cancer, prophylactic total colectomy is not
often performed in cases of LS, unlike that observed in
FAP [23].
Previous studies have reported that total colectomy
does not significantly improve the overall survival of LS
patients, and the surgical procedure should be selected
based on individual patient factors and preferences [24,
25]. Therefore, total colectomy should only be offered
under the following special circumstances: cases of
early-onset cancer or repeated episodes of cancer devel-
opment and patients in whom it is technically difficult
to perform colonoscopy or those with poor compliance
with surveillance examinations or who choose to
undergo colectomy rather than surveillance [9]. It is im-
portant to communicate with the patient regarding the
expectations and future risks associated with either op-
tion with respect to the risk of cancer in the remaining
colon and the potential for functional depression after
removing the entire colorectum [6, 21, 22]. The follow-
ing information also assists in the selection process: the
location of the tumor, existence of colonic disease, age,
comorbidities, and the baseline bowel/sphincter function
[24].
In the present case, despite undergoing annual colon-
oscopy, the patient was found to have CRC at an ad-
vanced stage. He had previously undergone proctectomy
for UC, segmental colectomy for CRC and distal gastrec-
tomy for gastric cancer. There is a possibility that the
presence of abdominal adhesion due to the use of mul-
tiple surgeries made it technically difficult to adequately
perform colonoscopy. Considering factors such as the
patient’s age, the technical difficulty in examining the
colonoscopy findings, and the frequency of metachro-
nous CRC, we recommended that he undergo total col-
ectomy. He had previously undergone proctectomy for
UC; therefore, we chose total colectomy with ileostomy,
not ileorectal anastomosis. Since the patient had under-
gone colostomy placement in his 20s, he was able to adapt
to the ileostomy following the removal of the entire color-
ectum. To the best our knowledge, no previous reports
have indicated a relationship between UC and LS.
Patients with LS are not often diagnosed at the time of
surgery. Therefore, it is important to consider the possi-
bility of LS in individuals with a characteristic family his-
tory, past medical history, and pathological tissue
findings. If LS is suspected, the physician should attempt
to perform an MSI analysis, immunohistochemistry, and
germline mutation analysis. After the diagnosis, it is ne-
cessary to carefully consider the indication for total col-
ectomy based on the patient’s history. In the present
case, we were able to strongly suggest LS before surgery
by conducting an MSI analysis of both previously
resected specimens.
Conclusions
There is concern regarding the selection of the surgical
procedure in cases of CRC in LS patients. Prophylactic
total colectomy should be considered in patients with a
high frequency of CRC in whom it is difficult to prevent
progression to advanced cancer due to rapid tumor
development.
In addition, our findings emphasize the significance of
making a preoperative diagnosis of LS. It is important to
suggest LS preoperatively using MSI analyses and immu-
nohistochemistry in cases involving a characteristic fam-
ily history, past medical history and pathological findings
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in biopsy specimens. The present case provided import-
ant information on the clinical management of multiple
developing metachronous colorectal cancers in patients
with LS.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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